Do analysts prefer CGEN or EXOZ?

Compugen currently has a consensus price target of $5.00, indicating a potential upside of 100.80%. Given Compugen's stronger consensus rating and higher possible upside, equities research analysts clearly believe Compugen is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Compugen 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.00 eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CGEN or EXOZ more profitable?

Compugen has a net margin of 47.56% compared to eXoZymes' net margin of 0.00%. Compugen's return on equity of 42.57% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets Compugen 47.56% 42.57% 26.13% eXoZymes N/A -292.15% -158.66%

Do analysts prefer IVVD or EXOZ?

Invivyd presently has a consensus target price of $8.00, suggesting a potential upside of 959.18%. Given Invivyd's stronger consensus rating and higher probable upside, research analysts plainly believe Invivyd is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invivyd 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is IVVD or EXOZ more profitable?

eXoZymes has a net margin of 0.00% compared to Invivyd's net margin of -183.90%. Invivyd's return on equity of -59.73% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets Invivyd -183.90% -59.73% -48.97% eXoZymes N/A -292.15% -158.66%

Do analysts prefer EXOZ or GLSI?

Greenwich LifeSciences has a consensus price target of $69.00, indicating a potential upside of 263.35%. Given Greenwich LifeSciences' stronger consensus rating and higher probable upside, analysts clearly believe Greenwich LifeSciences is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Greenwich LifeSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is EXOZ or GLSI more profitable?

eXoZymes' return on equity of -292.15% beat Greenwich LifeSciences' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -292.15% -158.66% Greenwich LifeSciences N/A -793.81% -295.32%

Do analysts rate ELDN or EXOZ?

Eledon Pharmaceuticals currently has a consensus price target of $10.00, suggesting a potential upside of 281.68%. Given Eledon Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Eledon Pharmaceuticals is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eledon Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ELDN or EXOZ more profitable?

Eledon Pharmaceuticals' return on equity of -149.63% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets Eledon Pharmaceuticals N/A -149.63% -50.84% eXoZymes N/A -292.15% -158.66%

Do analysts recommend EXOZ or TARA?

Protara Therapeutics has a consensus target price of $26.25, suggesting a potential upside of 639.44%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Protara Therapeutics is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Protara Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75

Is EXOZ or TARA more profitable?

Protara Therapeutics' return on equity of -41.72% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -292.15% -158.66% Protara Therapeutics N/A -41.72% -38.78%

eXoZymes (EXOZ) Competitors

$6.43 +0.24 (+3.88%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$6.47 +0.04 (+0.56%)

As of 09/18/2026 06:34 PM Eastern

Compare

EXOZ vs. CGEN, IVVD, GLSI, ELDN, and TARA

Should you buy eXoZymes stock or one of its competitors? eXoZymes's main competitors and comparable companies include Compugen (CGEN), Invivyd (IVVD), Greenwich LifeSciences (GLSI), Eledon Pharmaceuticals (ELDN), and Protara Therapeutics (TARA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does eXoZymes compare to Compugen?

Compugen (NASDAQ:CGEN) and eXoZymes (NASDAQ:EXOZ) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Compugen currently has a consensus price target of $5.00, indicating a potential upside of 100.80%. Given Compugen's stronger consensus rating and higher possible upside, equities research analysts clearly believe Compugen is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compugen	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Compugen has a net margin of 47.56% compared to eXoZymes' net margin of 0.00%. Compugen's return on equity of 42.57% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Compugen	47.56%	42.57%	26.13%
eXoZymes	N/A	-292.15%	-158.66%

In the previous week, Compugen had 1 more articles in the media than eXoZymes. MarketBeat recorded 1 mentions for Compugen and 0 mentions for eXoZymes. Compugen's average media sentiment score of 0.67 beat eXoZymes' score of 0.00 indicating that Compugen is being referred to more favorably in the media.

Company	Overall Sentiment
Compugen	Positive
eXoZymes	Neutral

12.2% of Compugen shares are owned by institutional investors. 9.5% of Compugen shares are owned by insiders. Comparatively, 72.4% of eXoZymes shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Compugen has higher revenue and earnings than eXoZymes. eXoZymes is trading at a lower price-to-earnings ratio than Compugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compugen	$72.76M	3.24	$35.34M	$0.38	6.55
eXoZymes	$70K	852.43	-$9.16M	-$1.19	N/A

Compugen has a beta of 2.78, meaning that its share price is 178% more volatile than the broader market. Comparatively, eXoZymes has a beta of 3.14, meaning that its share price is 214% more volatile than the broader market.

Summary

Compugen beats eXoZymes on 14 of the 17 factors compared between the two stocks.

How does eXoZymes compare to Invivyd?

Invivyd (NASDAQ:IVVD) and eXoZymes (NASDAQ:EXOZ) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Invivyd presently has a consensus target price of $8.00, suggesting a potential upside of 959.18%. Given Invivyd's stronger consensus rating and higher probable upside, research analysts plainly believe Invivyd is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

eXoZymes has a net margin of 0.00% compared to Invivyd's net margin of -183.90%. Invivyd's return on equity of -59.73% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invivyd	-183.90%	-59.73%	-48.97%
eXoZymes	N/A	-292.15%	-158.66%

In the previous week, Invivyd had 3 more articles in the media than eXoZymes. MarketBeat recorded 3 mentions for Invivyd and 0 mentions for eXoZymes. Invivyd's average media sentiment score of 0.15 beat eXoZymes' score of 0.00 indicating that Invivyd is being referred to more favorably in the media.

Company	Overall Sentiment
Invivyd	Neutral
eXoZymes	Neutral

eXoZymes has lower revenue, but higher earnings than Invivyd. eXoZymes is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$53.43M	4.17	-$52.49M	-$0.33	N/A
eXoZymes	$70K	852.43	-$9.16M	-$1.19	N/A

70.4% of Invivyd shares are owned by institutional investors. 12.3% of Invivyd shares are owned by company insiders. Comparatively, 72.4% of eXoZymes shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Invivyd has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market. Comparatively, eXoZymes has a beta of 3.14, meaning that its stock price is 214% more volatile than the broader market.

Summary

Invivyd beats eXoZymes on 11 of the 16 factors compared between the two stocks.

How does eXoZymes compare to Greenwich LifeSciences?

eXoZymes (NASDAQ:EXOZ) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

In the previous week, Greenwich LifeSciences had 1 more articles in the media than eXoZymes. MarketBeat recorded 1 mentions for Greenwich LifeSciences and 0 mentions for eXoZymes. eXoZymes' average media sentiment score of 0.00 beat Greenwich LifeSciences' score of -1.32 indicating that eXoZymes is being referred to more favorably in the media.

Company	Overall Sentiment
eXoZymes	Neutral
Greenwich LifeSciences	Negative

eXoZymes' return on equity of -292.15% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-292.15%	-158.66%
Greenwich LifeSciences	N/A	-793.81%	-295.32%

eXoZymes has a beta of 3.14, suggesting that its share price is 214% more volatile than the broader market. Comparatively, Greenwich LifeSciences has a beta of 1.47, suggesting that its share price is 47% more volatile than the broader market.

Greenwich LifeSciences has a consensus price target of $69.00, indicating a potential upside of 263.35%. Given Greenwich LifeSciences' stronger consensus rating and higher probable upside, analysts clearly believe Greenwich LifeSciences is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

4.2% of Greenwich LifeSciences shares are held by institutional investors. 72.4% of eXoZymes shares are held by company insiders. Comparatively, 51.5% of Greenwich LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

eXoZymes has higher revenue and earnings than Greenwich LifeSciences. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than eXoZymes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	852.43	-$9.16M	-$1.19	N/A
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.54	N/A

Summary

eXoZymes beats Greenwich LifeSciences on 9 of the 14 factors compared between the two stocks.

How does eXoZymes compare to Eledon Pharmaceuticals?

Eledon Pharmaceuticals (NASDAQ:ELDN) and eXoZymes (NASDAQ:EXOZ) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, analyst recommendations, profitability, dividends and valuation.

Eledon Pharmaceuticals currently has a consensus price target of $10.00, suggesting a potential upside of 281.68%. Given Eledon Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Eledon Pharmaceuticals is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Eledon Pharmaceuticals' average media sentiment score of 0.00 equaled eXoZymes'average media sentiment score.

Company	Overall Sentiment
Eledon Pharmaceuticals	Neutral
eXoZymes	Neutral

Eledon Pharmaceuticals' return on equity of -149.63% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-149.63%	-50.84%
eXoZymes	N/A	-292.15%	-158.66%

Eledon Pharmaceuticals has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, eXoZymes has a beta of 3.14, suggesting that its stock price is 214% more volatile than the broader market.

56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. 9.6% of Eledon Pharmaceuticals shares are owned by company insiders. Comparatively, 72.4% of eXoZymes shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

eXoZymes has higher revenue and earnings than Eledon Pharmaceuticals. eXoZymes is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.91	N/A
eXoZymes	$70K	852.43	-$9.16M	-$1.19	N/A

Summary

Eledon Pharmaceuticals beats eXoZymes on 8 of the 12 factors compared between the two stocks.

How does eXoZymes compare to Protara Therapeutics?

eXoZymes (NASDAQ:EXOZ) and Protara Therapeutics (NASDAQ:TARA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, analyst recommendations, media sentiment, earnings, dividends, valuation and profitability.

In the previous week, eXoZymes' average media sentiment score of 0.00 equaled Protara Therapeutics'average media sentiment score.

Company	Overall Sentiment
eXoZymes	Neutral
Protara Therapeutics	Neutral

Protara Therapeutics' return on equity of -41.72% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-292.15%	-158.66%
Protara Therapeutics	N/A	-41.72%	-38.78%

eXoZymes has higher revenue and earnings than Protara Therapeutics. eXoZymes is trading at a lower price-to-earnings ratio than Protara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	852.43	-$9.16M	-$1.19	N/A
Protara Therapeutics	N/A	N/A	-$57.44M	-$1.35	N/A

Protara Therapeutics has a consensus target price of $26.25, suggesting a potential upside of 639.44%. Given Protara Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Protara Therapeutics is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Protara Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

38.1% of Protara Therapeutics shares are held by institutional investors. 72.4% of eXoZymes shares are held by insiders. Comparatively, 7.6% of Protara Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

eXoZymes has a beta of 3.14, meaning that its share price is 214% more volatile than the broader market. Comparatively, Protara Therapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

Summary

Protara Therapeutics beats eXoZymes on 7 of the 12 factors compared between the two stocks.

Get eXoZymes News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EXOZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EXOZ vs. The Competition

Export

Metric	eXoZymes	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$59.73M	$3.89B	$7.24B	$12.95B
Dividend Yield	N/A	3.64%	2.57%	12.80%
P/E Ratio	-5.40	14.23	275.21	25.38
Price / Sales	852.43	1,459.32	665.54	96.26
Price / Cash	N/A	41.62	28.13	34.74
Price / Book	16.08	15.47	10.50	6.32
Net Income	-$9.16M	-$22.90M	$3.49B	$358.20M
7 Day Performance	-2.58%	-1.21%	0.59%	1.12%
1 Month Performance	-8.66%	-3.29%	-1.74%	-2.39%
1 Year Performance	-55.56%	37.74%	18.13%	5.35%

eXoZymes Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EXOZ eXoZymes	0.527 of 5 stars	$6.43 +3.9%	N/A	-55.6%	$59.73M	$70K	N/A	32	High Trading Volume
CGEN Compugen	3.9091 of 5 stars	$2.47 +0.4%	$5.00 +102.4%	+87.2%	$233.55M	$72.76M	6.50	70
IVVD Invivyd	3.3992 of 5 stars	$0.79 +1.2%	$8.00 +918.5%	-38.1%	$231.53M	$53.43M	N/A	100
GLSI Greenwich LifeSciences	2.0457 of 5 stars	$15.45 +2.6%	$69.00 +346.6%	+65.7%	$226.78M	N/A	N/A	3	Negative News
ELDN Eledon Pharmaceuticals	1.2879 of 5 stars	$2.78 flat	$10.00 +259.7%	+2.7%	$225.91M	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EXOZ) was last updated on 9/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

eXoZymes (EXOZ) Competitors

EXOZ vs. CGEN, IVVD, GLSI, ELDN, and TARA

How does eXoZymes compare to Compugen?

Summary

How does eXoZymes compare to Invivyd?

Summary

How does eXoZymes compare to Greenwich LifeSciences?

Summary

How does eXoZymes compare to Eledon Pharmaceuticals?

Summary

How does eXoZymes compare to Protara Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXOZ vs. The Competition

eXoZymes Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

eXoZymes (EXOZ) Competitors

EXOZ vs. CGEN, IVVD, GLSI, ELDN, and TARA

How does eXoZymes compare to Compugen?

Do analysts prefer CGEN or EXOZ?

Is CGEN or EXOZ more profitable?

Does the media prefer CGEN or EXOZ?

Do institutionals and insiders have more ownership in CGEN or EXOZ?

Which has preferable valuation and earnings, CGEN or EXOZ?

Which has more risk & volatility, CGEN or EXOZ?

Summary

How does eXoZymes compare to Invivyd?

Do analysts prefer IVVD or EXOZ?

Is IVVD or EXOZ more profitable?

Does the media favor IVVD or EXOZ?

Which has stronger earnings & valuation, IVVD or EXOZ?

Do institutionals & insiders have more ownership in IVVD or EXOZ?

Which has more volatility & risk, IVVD or EXOZ?

Summary

How does eXoZymes compare to Greenwich LifeSciences?

Does the media refer more to EXOZ or GLSI?

Is EXOZ or GLSI more profitable?

Which has more volatility and risk, EXOZ or GLSI?

Do analysts prefer EXOZ or GLSI?

Do institutionals and insiders believe in EXOZ or GLSI?

Which has preferable earnings & valuation, EXOZ or GLSI?

Summary

How does eXoZymes compare to Eledon Pharmaceuticals?

Do analysts rate ELDN or EXOZ?

Does the media prefer ELDN or EXOZ?

Is ELDN or EXOZ more profitable?

Which has more volatility & risk, ELDN or EXOZ?

Do institutionals & insiders hold more shares of ELDN or EXOZ?

Which has better earnings & valuation, ELDN or EXOZ?

Summary

How does eXoZymes compare to Protara Therapeutics?

Does the media refer more to EXOZ or TARA?

Is EXOZ or TARA more profitable?

Which has better valuation and earnings, EXOZ or TARA?

Do analysts recommend EXOZ or TARA?

Do institutionals and insiders have more ownership in EXOZ or TARA?

Which has more volatility & risk, EXOZ or TARA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXOZ vs. The Competition

eXoZymes Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools